US-based DirectBio is a diagnostics company developing a faster, cheaper, and more accurate way to test for diseases using CRISPR technology. Unlike traditional PCR tests, its approach does not need DNA amplification or specialized lab equipment, which can reduce testing time and make diagnostics easier to use in more settings. DirectBio’s technology can also test for multiple viruses, bacteria, or biomarkers from a single sample, helping healthcare providers detect disease more efficiently and potentially replacing older testing methods over time.